Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Daudignon A et al. Ann Biol Clin (Paris). 2016 Oct 1;74(5):588-595.

Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Sawyer JR et al. Leukemia. 2016 Oct 3. doi: 10.1038/leu.2016.253. [Epub ahead of print].

Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.
Yuan M et al. Mol Med Rep. 2016 Oct 24. doi: 10.3892/mmr.2016.5879. [Epub ahead of print].

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.
Barbado MV et al. Int J Cancer. 2016 Oct 25. doi: 10.1002/ijc.30483. [Epub ahead of print].

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A et al. Nature. 2016 Oct 19. doi: 10.1038/nature19830. [Epub ahead of print].

miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells.
Wu SQ et al. Mol Med Rep. 2016 Nov;14(5):4795-4801. doi: 10.3892/mmr.2016.5832. Epub 2016 Oct 12.

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
Alonso S et al. J Clin Invest. 2016 Oct 24. pii: 88152. doi: 10.1172/JCI88152. [Epub ahead of print].

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.
van Andel H et al. Oncogene. 2016 Oct 24. doi: 10.1038/onc.2016.368. [Epub ahead of print].

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
Manier S et al. Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.296. [Epub ahead of print].

Intercriteria analysis of calorimetric data of blood serum proteome.
Krumova S et al. Biochim Biophys Acta. 2016 Oct 15. pii: S0304-4165(16)30387-7. doi: 10.1016/j.bbagen.2016.10.012. [Epub ahead of print].

Role and mechanism of action of sclerostin in bone.
Delgado-Calle J et al. Bone. 2016 Oct 12. pii: S8756-3282(16)30297-6. doi: 10.1016/j.bone.2016.10.007. [Epub ahead of print].

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.
Das R et al. Nat Med. 2016 Oct 10. doi: 10.1038/nm.4202. [Epub ahead of print].

Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P et al. Cancer Lett. 2016 Sep 30;383(2):204-211. doi: 10.1016/j.canlet.2016.09.030. [Epub ahead of print].

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP et al. Bioorg Med Chem Lett. 2016 Oct 1. pii: S0960-894X(16)31016-2. doi: 10.1016/j.bmcl.2016.09.067. [Epub ahead of print].

Distinct and shared three-dimensional chromosome organization patterns in lymphocytes, monoclonal gammopathy of undetermined significance and multiple myeloma.
Sathitruangsak C et al. Int J Cancer. 2016 Oct 6. doi: 10.1002/ijc.30461. [Epub ahead of print].

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Nabissi M et al. Oncotarget. 2016 Oct 18. doi: 10.18632/oncotarget.12721. [Epub ahead of print].

4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways.
Liang Y et al. Cancer Invest. 2016 Oct 21:1-10. [Epub ahead of print].

The effect of microenvironmental factors on the development of myeloma cells.
Márk Á et al. Hematol Oncol. 2016 Oct 21. doi: 10.1002/hon.2354. [Epub ahead of print].

Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma.
Tucci M et al. Exp Hematol. 2016 Oct 17. pii: S0301-472X(16)30659-2. doi: 10.1016/j.exphem.2016.10.004. [Epub ahead of print].

Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
Zhang J et al. Bioorg Med Chem. 2016 Oct 6. pii: S0968-0896(16)30896-3. doi: 10.1016/j.bmc.2016.10.002. [Epub ahead of print].

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
Jakubikova J et al. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12643. [Epub ahead of print].

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies – a short report.
Caivano A et al. Cell Oncol (Dordr). 2016 Oct 19. [Epub ahead of print].

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.
Horenstein AL et al. Mol Med. 2016 Oct 13;22. doi: 10.2119/molmed.2016.00198. [Epub ahead of print].

Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.
Vardaki I et al. Blood. 2016 Oct 14. pii: blood-2016-05-715961. [Epub ahead of print].

The Sphingosine 1 Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
Beider K et al. Clin Cancer Res. 2016 Oct 3. pii: clincanres.2618.2015. [Epub ahead of print].

Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.
Pau Ni IB et al. Bosn J Basic Med Sci. 2016 Oct 18. doi: 10.17305/bjbms.2016.1568. [Epub ahead of print].

TRAF3 deficiency promotes metabolic reprogramming in B cells.
Mambetsariev N et al. Sci Rep. 2016 Oct 18;6:35349. doi: 10.1038/srep35349.

DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q et al. Drug Deliv. 2016 Oct 17:1-10. [Epub ahead of print].

Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J et al. Br J Haematol. 2016 Oct 17. doi: 10.1111/bjh.14388. [Epub ahead of print].

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A et al. Oncotarget. 2016 Oct 12. doi: 10.18632/oncotarget.12594. [Epub ahead of print].

Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
Raninga PV et al. Apoptosis. 2016 Oct 12. [Epub ahead of print].

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S et al. Oncotarget. 2016 Oct 8. doi: 10.18632/oncotarget.12522. [Epub ahead of print].

The IgH 3′ regulatory region and c-myc-induced B-cell lymphomagenesis.
Ghazzaui N et al. Oncotarget. 2016 Oct 8. doi: 10.18632/oncotarget.12535. [Epub ahead of print].

Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.
Norris EJ et al. Blood Cancer J. 2016 Oct 7;6(10):e480. doi: 10.1038/bcj.2016.92.

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.
Losada A et al. Sci Rep. 2016 Oct 7;6:35100. doi: 10.1038/srep35100.

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM).
Tibullo D et al. Nutrients. 2016 Oct 1;8(10). pii: E611.

An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway.
Xu X et al. Oncotarget. 2016 Sep 26. doi: 10.18632/oncotarget.12265. [Epub ahead of print].

Impact of metformin on the progression of MGUS to multiple myeloma.
Boursi B et al. Leuk Lymphoma. 2016 Oct 5:1-3. [Epub ahead of print].

Src Family Kinases are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.
Abdollahi P et al. Mol Cancer Res. 2016 Oct 3. pii: molcanres.0212.2016. [Epub ahead of print].

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Müller E et al. Leukemia. 2016 Sep 30. doi: 10.1038/leu.2016.264. [Epub ahead of print].

Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes bortezomib resistance in multiple myeloma.
Malek E et al. Leukemia. 2016 Sep 28. doi: 10.1038/leu.2016.258. [Epub ahead of print].